LONG BEACH, Calif. — In this video from the American Society of Retina Specialists annual meeting, Arshad M. Khanani, MD, MA, FASRS , discusses PER-001 , an endothelin antagonist from Perfuse Therapeutics, for diabetic retinopathy.

“This is a really exciting new mechanism of action for our field, hoping to improve functional as well as structural outcomes for our patients with diabetic retinopathy and hopefully [age-related macular degeneration],” Khanani, of Sierra Eye Associates in Reno, Nevada, told Healio.

See Full Page